# Herbal Remedies for Autism and ADHD: Research Summary

**Research Date:** February 3, 2026  
**Researcher:** Scout üîç (Subagent)  
**Sources:** PubMed, peer-reviewed journals, systematic reviews, and meta-analyses

---

## Executive Summary

Current scientific evidence for herbal treatments in ADHD and autism spectrum disorder (ASD) ranges from **promising to preliminary**. While several herbs show potential, **no herbal treatment has sufficient evidence to replace conventional ADHD medications**. Most studies have methodological limitations including small sample sizes, short duration, and variable standardization of extracts.

---

## TIER 1: MOST PROMISING EVIDENCE

### 1. SAFFRON (Crocus sativus)

**Condition:** ADHD  
**Evidence Level:** ‚≠ê‚≠ê‚≠ê‚≠ê MODERATE-STRONG

#### Key Study:
**"Crocus sativus L. Versus Methylphenidate in Treatment of Children with ADHD: A Randomized, Double-Blind Pilot Study"**
- **Authors:** Baziar S, Aqamolaei A, Khadem E, et al.
- **Journal:** J Child Adolesc Psychopharmacol. 2019 Apr;29(3):205-212
- **PMID:** 30741567
- **DOI:** 10.1089/cap.2018.0146

**Study Design:** 6-week randomized, double-blind trial; 54 children (ages 6-17) with DSM-5 ADHD diagnosis

**Dosage:** 20-30 mg/day saffron capsules (20mg for <30kg, 30mg for >30kg body weight)

**Findings:** 
- **Saffron showed EQUIVALENT efficacy to methylphenidate** on Parent and Teacher ADHD-RS-IV scores
- No significant difference between groups at weeks 3 and 6
- Similar adverse effect profile to methylphenidate

**Limitations:** Small sample size, short duration, pilot study

#### Systematic Review (2024):
**"New horizons for the study of saffron...in neurological and psychiatric disorders"**
- **Authors:** Han S, Cao Y, Wu X, et al.
- **Journal:** Phytother Res. 2024 May;38(5):2276-2302
- **PMID:** 38424688

**Meta-analysis findings:** Saffron was non-inferior to conventional drugs for ADHD, showed good tolerance with few side effects.

**Safety:** Generally well-tolerated; mild GI symptoms possible
**Interactions:** May interact with anticoagulants; theoretical serotonergic effects

---

### 2. BACOPA MONNIERI (Brahmi)

**Condition:** ADHD, Cognitive Function  
**Evidence Level:** ‚≠ê‚≠ê‚≠ê‚≠ê MODERATE

#### Key Studies:

**Study 1: "Effects of Bacopa monnieri (CDRI 08¬Æ) in males aged 6-14 years: A randomized, double-blind, placebo-controlled trial"**
- **Authors:** Kean JD, Downey LA, Sarris J, et al.
- **Journal:** Phytother Res. 2022 Feb;36(2):996-1012
- **PMID:** 35041248

**Study Design:** 14-week RCT with placebo run-in/run-out; 112 male participants (6-14 years)

**Dosage:** CDRI 08¬Æ extract (standardized)

**Findings:**
- Did NOT significantly improve behavioral ADHD outcomes vs placebo
- **DID improve:** cognitive flexibility (p=.01), executive functioning (p=.04), interpersonal problems (p=.02), sleep routine (p=.04)
- Decreased error-making (p=.04)

---

**Study 2: Systematic Review of Bacopa in Children**
- **Authors:** Kean JD, Downey LA, Stough C
- **Journal:** Complement Ther Med. 2016 Dec;29:56-62
- **PMID:** 27912958

**Findings from 5 included studies:**
- Significant improvements in **language, memory, hyperactivity, and attention-deficit domains**
- Small to medium effect sizes (mean d=0.42)
- **Safety:** Only 2.3% reported mild side-effects; well-tolerated

---

**Meta-Analysis: "Meta-analysis of RCTs on cognitive effects of Bacopa monnieri"**
- **Authors:** Kongkeaw C, et al.
- **Journal:** J Ethnopharmacol. 2014;151(1):528-35
- **PMID:** 24252493

**Findings (9 studies, 518 subjects):**
- Improved cognition, particularly **speed of attention**
- Shortened Trail B test (-17.9 ms, p<0.001)
- Decreased choice reaction time (10.6 ms, p<0.001)

**Dosage in studies:** 300-450 mg standardized extract daily

**Safety:** Generally safe; GI effects possible; may enhance effects of sedatives

---

### 3. KOREAN RED GINSENG (Panax ginseng)

**Condition:** ADHD  
**Evidence Level:** ‚≠ê‚≠ê‚≠ê MODERATE

#### Key Study:
**"Effects of Korean red ginseng extract on behavior in children with ADHD symptoms: a double-blind randomized placebo-controlled trial"**
- **Authors:** Ko HJ, Kim I, Kim JB, et al.
- **Journal:** J Child Adolesc Psychopharmacol. 2014 Nov;24(9):501-8
- **PMID:** 25369174

**Study Design:** 8-week double-blind RCT; 70 children (6-15 years)

**Dosage:** 1g KRG extract twice daily (2g/day total)

**Findings:**
- **Significantly decreased** inattention scores (p=0.048) and hyperactivity scores (p=0.047) vs placebo
- **Decreased QEEG theta/beta ratio** (p=0.001) - neurophysiological marker of attention
- No significant changes in cortisol/DHEA levels

**Safety:** No serious adverse events reported

**Interactions:** May affect blood sugar; caution with anticoagulants, stimulants, MAOIs

---

## TIER 2: LIMITED BUT PROMISING EVIDENCE

### 4. PYCNOGENOL (French Maritime Pine Bark Extract)

**Condition:** ADHD  
**Evidence Level:** ‚≠ê‚≠ê LIMITED/MIXED

#### Key Studies:

**Study 1 (Negative):**
**"An experimental comparison of Pycnogenol and methylphenidate in adults with ADHD"**
- **Authors:** Tenenbaum S, Paull JC, et al.
- **Journal:** J Atten Disord. 2002 Sep;6(2):49-60
- **PMID:** 12142861

**Design:** Double-blind, placebo-controlled, crossover; 24 adults (24-53 years)

**Findings:** Neither Pycnogenol nor methylphenidate outperformed placebo (conservative dosing noted as limitation)

---

**Study 2 (Positive):**
**"Urinary catecholamines in children with ADHD: modulation by Pycnogenol"**
- **Authors:** Dvor√°kov√° M, et al.
- **Journal:** Nutr Neurosci. 2007 Jun-Aug;10(3-4):151-7
- **PMID:** 18019397

**Findings:** Reduced hyperactivity and catecholamine excretion

**Cochrane Review (2020):** Insufficient evidence to recommend for ADHD (PMID: 32990945)

**Dosage:** 1 mg/kg/day commonly used in studies

---

### 5. VALERIAN + PASSIONFLOWER + ST. JOHN'S WORT (Combination)

**Condition:** ADHD-related symptoms (agitation, anxiety, attention)  
**Evidence Level:** ‚≠ê‚≠ê LOW-MODERATE

#### Key Study:
**"Herbal triplet in treatment of nervous agitation in children"**
- **Authors:** Trompetter I, Krick B, Weiss G
- **Journal:** Wien Med Wochenschr. 2013 Feb;163(3-4):52-7
- **PMID:** 23179673

**Study Design:** Multicenter prospective observational study; 115 children (6-12 years)

**Findings:**
- Distinct improvement in **attention problems, social withdrawal, anxiety/depression**
- 81.6-93.9% had no or mild symptoms at end of observation
- Well tolerated

**‚ö†Ô∏è CRITICAL WARNING - ST. JOHN'S WORT:**
- **PMID 31670573** (2020): FDA adverse event reports show **probable/possible interactions between St. John's Wort and methylphenidate**
- St. John's Wort induces CYP3A4 - can reduce effectiveness of ADHD medications
- Can cause serotonin syndrome when combined with stimulants
- **DO NOT COMBINE WITH ADHD MEDICATIONS**

---

### 6. GINKGO BILOBA

**Condition:** ADHD  
**Evidence Level:** ‚≠ê‚≠ê LIMITED (inferior to standard treatment)

#### Key Study:
**"Ginkgo biloba for ADHD in children and adolescents: a double blind, randomized controlled trial"**
- **Authors:** Salehi B, Imani R, et al.
- **Journal:** Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb;34(1):76-80
- **PMID:** 19815048

**Study Design:** 6-week double-blind RCT; 50 children

**Dosage:** 80-120 mg/day (weight-based)

**Findings:** 
- **Ginkgo was LESS effective than methylphenidate**
- Parent scale: Ginkgo -6.52 vs MPH -15.92
- Teacher scale: Ginkgo -0.84 vs MPH -14.04

**Safety:** Fewer side effects than MPH (less appetite suppression, headache, insomnia)

---

## TIER 3: EMERGING EVIDENCE (CBD/CANNABIS)

### 7. CANNABIDIOL (CBD) - For Autism Spectrum Disorder

**Condition:** ASD (primarily)  
**Evidence Level:** ‚≠ê‚≠ê‚≠ê EMERGING/MODERATE (for ASD)

#### Key Studies:

**RCT: "Evaluation of CBD-rich cannabis extract in children with ASD"**
- **Authors:** Silva EAD Junior, Medeiros WMB, et al.
- **Journal:** Trends Psychiatry Psychother. 2024;46:e20210396
- **PMID:** 35617670

**Study Design:** 12-week double-blind, placebo-controlled RCT; 60 children (5-11 years)

**Findings:**
- **Significant improvements in:**
  - Social interaction (p=0.0002)
  - Anxiety (p=0.016)
  - Psychomotor agitation (p=0.003)
  - Concentration in mild ASD (p=0.01)
- Only 9.7% (3 children) had adverse effects: dizziness, insomnia, colic, weight gain

---

**Open Label Study:**
**"Children and adolescents with ASD treated with CBD-rich cannabis"**
- **Authors:** Hacohen M, et al.
- **Journal:** Transl Psychiatry. 2022 Sep;12(1):375
- **PMID:** 36085294

**Findings:** Significant improvements particularly in **social symptoms**

---

**Systematic Review:**
**"A systematic review of cannabidiol trials in neurodevelopmental disorders"**
- **Authors:** Parrella NF, et al.
- **Journal:** Pharmacol Biochem Behav. 2023 Sep;230:173607
- **PMID:** 37543051

**Findings:** 9 RCTs examined; ASD studies showed most consistent effects among neurodevelopmental disorders

---

**‚ö†Ô∏è FOR ADHD SPECIFICALLY:**

**Lancet Psychiatry Meta-Analysis (2019):**
**"Cannabinoids for the treatment of mental disorders"**
- **Authors:** Black N, et al.
- **Journal:** Lancet Psychiatry. 2019 Dec;6(12):995-1010
- **PMID:** 31672337

**Findings:** 
- Only **1 RCT** (n=30) examined cannabinoids for ADHD
- "**Scarce evidence**" that cannabinoids improve ADHD
- Increased adverse events and withdrawals compared to placebo
- "**Insufficient evidence to provide guidance**"

---

## TIER 4: INSUFFICIENT EVIDENCE

### Herbs with Little to No ADHD/ASD-Specific Research:

| Herb | Notes |
|------|-------|
| **Ashwagandha** | No pediatric ADHD/ASD clinical trials found; adult anxiety studies exist |
| **Rhodiola rosea** | No ADHD-specific clinical trials identified |
| **Chamomile** | Mentioned in systematic reviews as part of combinations; no standalone ADHD RCTs |
| **Lemon Balm (Melissa)** | Listed in systematic reviews with "low evidence"; limited standalone data |

---

## SYSTEMATIC REVIEWS SUMMARY

### "Herbal medicines in children with ADHD: A systematic review" (2017)
- **Authors:** Anheyer D, Lauche R, et al.
- **Journal:** Complement Ther Med. 2017 Feb;30:14-23
- **PMID:** 28137522

**Included:** 9 RCTs, 464 patients, 7 different herbs

**Evidence Grades:**
- **Low evidence:** Melissa officinalis, Valeriana officinalis, Passiflora incarnata
- **Limited evidence:** Pine bark extract, Ginkgo biloba
- **Other preparations:** No efficacy demonstrated

**Conclusion:** "No concrete recommendations for use can be made"

---

### "Phytotherapy for ADHD: Systematic Review and Meta-analysis" (2022)
- **Authors:** Dutta T, Anand U, et al.
- **Journal:** Front Pharmacol. 2022 May;13:827411
- **PMID:** 35592415

**Herbs with fair indication of efficacy and safety:**
1. Melissa officinalis
2. Bacopa monnieri
3. Matricaria chamomilla
4. Valeriana officinalis

**Limited evidence:** Ginkgo biloba, pine bark

**Conclusion:** "Inadequate proof to strongly support and recommend herbal medicines for ADHD"

---

### "Herbal Medicine in Autism Spectrum Disorder: A Systematic Review" (2018)
- **Authors:** Gasparotto FM, et al.
- **Journal:** Curr Drug Metab. 2018;19(5):454-459
- **PMID:** 29283066

**Included:** 23 studies (mostly preclinical); very limited controlled clinical data

**Conclusion:** "Available data do not yet allow us to suggest the effectiveness of herbal medicines as an add-on in the treatment of ASD symptoms"

---

## SAFETY CONSIDERATIONS & DRUG INTERACTIONS

### General Warnings:

1. **Quality control:** Herbal products vary significantly in potency and purity
2. **Not FDA-regulated as drugs:** May contain contaminants or undeclared ingredients
3. **Pediatric dosing:** Often extrapolated from adult data; limited pharmacokinetic studies in children

### Specific Interactions with ADHD Medications:

| Herb | Interaction Risk | Mechanism |
|------|------------------|-----------|
| **St. John's Wort** | ‚ö†Ô∏è HIGH | CYP3A4 induction reduces stimulant levels; serotonin syndrome risk |
| **Ginseng** | MODERATE | May affect blood sugar; additive stimulant effects |
| **Valerian** | LOW-MODERATE | May enhance sedation; timing issues with stimulants |
| **Ginkgo** | MODERATE | Anticoagulant effects; P-glycoprotein interactions |
| **CBD** | MODERATE | CYP450 inhibition; may increase levels of some medications |
| **Saffron** | LOW | Possible serotonergic effects |
| **Bacopa** | LOW | May enhance sedatives; theoretical cholinergic effects |

---

## CLINICAL RECOMMENDATIONS (Based on Current Evidence)

### For ADHD:
1. **Most promising:** Saffron (equivalent to MPH in one RCT - needs replication)
2. **For cognitive support (adjunct):** Bacopa monnieri
3. **May help with hyperactivity component:** Korean Red Ginseng
4. **Not recommended as monotherapy:** Any herbal treatment

### For ASD:
1. **Emerging evidence:** CBD-rich cannabis extracts (for social symptoms, anxiety)
2. **Insufficient evidence:** All other herbal approaches

### General Guidance:
- **Always consult healthcare provider** before starting any herbal supplement
- **Do not discontinue** prescribed ADHD medications without medical supervision
- **Avoid St. John's Wort** if taking ADHD medications
- **Use standardized extracts** when possible
- **Start low, go slow** with dosing

---

## FUTURE RESEARCH NEEDS

1. Larger, multi-center RCTs with longer follow-up
2. Head-to-head trials against active comparators (not just placebo)
3. Standardization of herbal preparations
4. Pharmacokinetic studies in pediatric populations
5. Long-term safety data
6. Combination studies (herbal + conventional treatment)

---

## REFERENCES (Organized by PMID)

| PMID | Citation |
|------|----------|
| 30741567 | Baziar S, et al. J Child Adolesc Psychopharmacol. 2019 (Saffron vs MPH) |
| 38424688 | Han S, et al. Phytother Res. 2024 (Saffron systematic review) |
| 35041248 | Kean JD, et al. Phytother Res. 2022 (Bacopa RCT in children) |
| 27912958 | Kean JD, et al. Complement Ther Med. 2016 (Bacopa systematic review) |
| 24252493 | Kongkeaw C, et al. J Ethnopharmacol. 2014 (Bacopa meta-analysis) |
| 25369174 | Ko HJ, et al. J Child Adolesc Psychopharmacol. 2014 (Korean Red Ginseng RCT) |
| 12142861 | Tenenbaum S, et al. J Atten Disord. 2002 (Pycnogenol adult study) |
| 18019397 | Dvor√°kov√° M, et al. Nutr Neurosci. 2007 (Pycnogenol catecholamines) |
| 23179673 | Trompetter I, et al. Wien Med Wochenschr. 2013 (Herbal triplet) |
| 19815048 | Salehi B, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2010 (Ginkgo RCT) |
| 31670573 | Mazhar H, et al. J Child Adolesc Psychopharmacol. 2020 (NHP-drug interactions) |
| 35617670 | Silva EAD Junior, et al. Trends Psychiatry Psychother. 2024 (CBD for ASD RCT) |
| 36085294 | Hacohen M, et al. Transl Psychiatry. 2022 (CBD for ASD open label) |
| 37543051 | Parrella NF, et al. Pharmacol Biochem Behav. 2023 (CBD neurodevelopmental review) |
| 31672337 | Black N, et al. Lancet Psychiatry. 2019 (Cannabinoids meta-analysis) |
| 28137522 | Anheyer D, et al. Complement Ther Med. 2017 (Herbal ADHD systematic review) |
| 35592415 | Dutta T, et al. Front Pharmacol. 2022 (Phytotherapy ADHD meta-analysis) |
| 29283066 | Gasparotto FM, et al. Curr Drug Metab. 2018 (Herbal ASD systematic review) |
| 32990945 | Robertson NU, et al. Cochrane Database Syst Rev. 2020 (Pine bark review) |
| 29575228 | Sarris J. Phytother Res. 2018 (Herbal medicines in psychiatric disorders) |

---

*Disclaimer: This research summary is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any treatment.*
